Skip to main content
Premium Trial:

Request an Annual Quote

GSK Expands Valentis Gene Expression License

NEW YORK, Dec. 17-GlaxoSmithKline has expanded its license to Valentis' gene expression technology, Valentis said today.


The two companies agreed in April 2001that the pharmaceutical company would have access to GeneSwitch, a technology that allows researchers to control activity of select genes in transgenic animals or cell cultures.


Under the current expanded agreement, GlaxoSmithKline will have  nonexclusive access to the technology for up to 10 years. Valentis will receive $1 million and continued rights to the clinical applications of the technology.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.